New Zealand - English - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - soya oil 30%{relative};  ;   - solution for infusion - 30 % - active: soya oil 30%{relative}     excipient: egg lecithin glycerol water for injection - part of the intravenous diet in all parenteral nutrition indications including: - preoperative and postoperative nutritional disturbances where an improved nitrogen balance is required; - nutritional disorders or disturbances of nitrogen balance due to inadequate or failing intestinal absorption caused by tumours in the gastrointestinal tract, acute or chronic intestinal diseases (peritonitis, ulcerative colitis, terminal ileitis); - burns, to reduce the frequently excessive nitrogen losses; - prolonged unconsciousness, eg following cranial trauma or poisoning in cases where enteral feeding is inappropriate or impossible; - impaired renal function where a concentrated source of energy may be indicated to reduce protein breakdown; - cachexia and - patients with essential fatty acid deficiency who cannot maintain or restore a normal essential fatty acid pattern by oral intake.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - soya oil, quantity: 0 qs; olive oil, quantity: 0 qs - injection, emulsion - excipient ingredients: water for injections; ascorbyl palmitate; glycerol; sodium oleate; sodium hydroxide; egg lecithin - parenteral nutrition when oral or enteral nutrition is impossible, insufficient or contraindicated.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - olive oil, quantity: 0 qs; soya oil, quantity: 0 qs - injection, emulsion - excipient ingredients: sodium oleate; egg lecithin; sodium hydroxide; glycerol; ascorbyl palmitate; water for injections - parenteral nutrition when oral or enteral nutrition is impossible, insufficient or contraindicated.

New Zealand - English - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - soya oil 10%{relative};  ;   - solution for infusion - 10 % - active: soya oil 10%{relative}     excipient: egg lecithin glycerol water for injection - part of the intravenous diet in all parenteral nutrition indications including: - preoperative and postoperative nutritional disturbances where an improved nitrogen balance is required; - nutritional disorders or disturbances of nitrogen balance due to inadequate or failing intestinal absorption caused by tumours in the gastrointestinal tract, acute or chronic intestinal diseases (peritonitis, ulcerative colitis, terminal ileitis); - burns, to reduce the frequently excessive nitrogen losses; - prolonged unconsciousness, eg following cranial trauma or poisoning in cases where enteral feeding is inappropriate or impossible; - impaired renal function where a concentrated source of energy may be indicated to reduce protein breakdown; - cachexia and - patients with essential fatty acid deficiency who cannot maintain or restore a normal essential fatty acid pattern by oral intake.

New Zealand - English - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - soya oil 20%{relative};  ;   - solution for infusion - 20 % - active: soya oil 20%{relative}     excipient: egg lecithin glycerol water for injection - part of the intravenous diet in all parenteral nutrition indications including: - preoperative and postoperative nutritional disturbances where an improved nitrogen balance is required; - nutritional disorders or disturbances of nitrogen balance due to inadequate or failing intestinal absorption caused by tumours in the gastrointestinal tract, acute or chronic intestinal diseases (peritonitis, ulcerative colitis, terminal ileitis); - burns, to reduce the frequently excessive nitrogen losses; - prolonged unconsciousness, eg following cranial trauma or poisoning in cases where enteral feeding is inappropriate or impossible; - impaired renal function where a concentrated source of energy may be indicated to reduce protein breakdown; - cachexia and - patients with essential fatty acid deficiency who cannot maintain or restore a normal essential fatty acid pattern by oral intake.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - soya oil, quantity: 300 g/l - injection, intravenous infusion - excipient ingredients: egg lecithin; water for injections; sodium hydroxide; glycerol - indications: part of the intravenous diet in all parenteral nutrition indications including:- 1. preoperative and postoperative nutritional disturbances where an improved nitrogen balance is required; 2. nutritional disorders or disturbances of nitrogen balance due to inadequate or failing intestinal absorption caused by tumours in the gastrointestinal tract, acute or chronic intestinal diseases (peritonitis, ulcerative colitis, terminal ileitis); 3. burns, to reduce the frequently-excessive nitrogen losses; 4. prolonged unconsciousness, eg. following cranial trauma or poisoning in cases where enteral feeding is inappropriate or impossible; 5.impaired renal function where a concentrated source of energy may be indicated to reduce protein breakdown; 6. cachexia; 7. patients with essential fatty acid deficiency who cannot maintain or restore a normal essential fatty acid pattern by oral intake. intralipid 30% is particularly suitable for patients on fluid restriction due to its more concentrated form. this also provides an advantage in patients with a high energy requirement. a lower phospholipid/triglyceride ratio provides less phospholipids than the same amount of energy from intralipid 200mg/l. about 60% of the fatty acids in intralipid are essential fatty acids.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - soya oil, quantity: 300 g/l - injection, intravenous infusion - excipient ingredients: glycerol; egg lecithin; sodium hydroxide; water for injections - indications: part of the intravenous diet in all parenteral nutrition indications including:- 1. preoperative and postoperative nutritional disturbances where an improved nitrogen balance is required; 2. nutritional disorders or disturbances of nitrogen balance due to inadequate or failing intestinal absorption caused by tumours in the gastrointestinal tract, acute or chronic intestinal diseases (peritonitis, ulcerative colitis, terminal ileitis); 3. burns, to reduce the frequently-excessive nitrogen losses; 4. prolonged unconsciousness, eg. following cranial trauma or poisoning in cases where enteral feeding is inappropriate or impossible; 5.impaired renal function where a concentrated source of energy may be indicated to reduce protein breakdown; 6. cachexia; 7. patients with essential fatty acid deficiency who cannot maintain or restore a normal essential fatty acid pattern by oral intake. intralipid 30% is particularly suitable for patients on fluid restriction due to its more concentrated form. this also provides an advantage in patients with a high energy requirement. a lower phospholipid/triglyceride ratio provides less phospholipids than the same amount of energy from intralipid 200mg/l. about 60% of the fatty acids in intralipid are essential fatty acids.

Ireland - English - HPRA (Health Products Regulatory Authority)

fresenius kabi limited - soya oil - emulsion for infusion - 30 per cent

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

almirall ltd - soya oil - bath additive - 847.5mg/1gram

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - soya oil -